Relief - Targeted CBD Blends+ - 100% Pure CBD
Relief - Targeted CBD Blends+ - 100% Pure CBD

Relief - Targeted CBD Blends+

100% Pure CBD
Regular price
Regular price
Sale price
Unit price
Sold out

Pure CBD Blends range are made with CBD isolate.

Relief+ CBD oil’s combine pure Cannabidiol [CBD] isolate with our special blend of highly targeted potentiation factors formulated specifically to treat side effects related to stress, anxiety and attention deficit disorders.

All “Pure CBD Blends” by 100% Pure CBD is formulated in certified organic, non-GMO, Canadian sourced hemp seed oil, organically sourced 99.9% pure CBD isolate and certified organic food-grade bio-enhancing isolates.

In addition, all Pure CBD Blends by 100% Pure CBD come fortified with our exclusive nanoparticle CBD delivery technology allowing for maximum bioavailability and targeted conversion to CB2 receptor.

The future of targeted CBD delivery is available exclusively at 100% Pure CBD & Hemplements_au

Terpenes Profile

These are a few of the known terpenes in our “Relief+” Blend that are known to enhance and provide more relief in such areas. 

Alpha Pinene 3.23mg/g

Beta Caryophyllene 3.10mg/g

These specific terpenes are known for their beneficial compounds such as: 

Alpha and Beta Pinene are terpenes largely found in conifers including pine and are often found together. They have both been found to elicit a swathe of beneficial effects, including antibiotic resistance modulation, anticoagulant, antitumor, antimicrobial, antimalarial, antioxidant, anti-inflammatory, anti-Leishmania, analgesic, cytogenetic, gastroprotective, anxiolytic, cytoprotective, anticonvulsant, neuroprotective, antioxidant, pancreatitis-reducing, anti-stress and anti-hyperthermia effects. - Read More

(Beta) β-caryophyllene is a major plant volatile found in large amounts in the essential oils of many different spice and food plants such as oregano (Origanum vulgare L.), cinnamon (Cinnamomum spp.) and black pepper (Piper nigrum I.).
In the gastrointestinal tract CB2 receptor agonists have been shown to prevent experimental colitis by reducing inflammation. Moreover, the CB2 receptor has been described as a potential target for the treatment of atherosclerosis and osteoporosis. Consequently, CB2 receptor-selective agonists that are devoid of the psychoactive side effects typically associated with CB1 receptor activation are potential drug candidates for the treatment of a range of different diseases. - Read More